SelfCAD Releases Lasso Selection

Feb 19, 2024 | Business

 SelfCAD just released the Lasso Selection, an option to select objects, or regions of the object like Faces or Vertices within the freely drawn range.

Lasso Selection was one of the most requested features by people transitioning from 2D to 3D design. It’s a drawing selection tool that is very popular in 2D design software like Photoshop. It allows users to select objects or parts of those objects (such as faces or vertices) within the drawn range, providing both precise and flexible selection tool for editing.

It’s not just the tool for designers switching from 2D to 3D. Everyone will benefit from it, especially beginners and people occasionally using 3D software, as it offers an option to draw and select organic shapes. It will streamline the more monotonous parts of 3D design and allow users to focus on what really matters.

SelfCAD expanded this tool as well. On top of the basic version, which allows you to select objects entirely or just partially enclosed within the drawn range, SelfCAD added options to select objects that directly intersect with the drawn line. You just need to select the required option from the drop-down menu.

About SelfCAD
SelfCAD is an all-in-one 3D modeling software, allowing you to design anything 3D from start to finish. You can design objects from scratch, or import and edit objects from the web to create realistic redenders, or slice them for 3D printing.

SelfCAD
Igor Idzik
+1 (845) 641-9136
https://www.selfcad.com

ContactContact

Categories

  • Graphics, Printing & CAD

SinoMab Awared the “Best Small and Mid-Cap Company” and “Best CEO” in the Selection of the “6th Hong Kong Golden Stocks Awards” and the “Listed Company with the Most Growth Potential” in the Selection of “2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies”

Jan 12, 2022 | Business

SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, was awarded the “Best Small and Medium-Cap Company” at the “6th Hong Kong Golden Stocks Awards Ceremony” held in Shenzhen today, and Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of the Company, was awarded the “Best CEO”. The Company was also previously awarded the “Listed Company with Most Growth Potential” in the selection of “2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies”.
SinoMab completed enrollment in the phase III clinical trial of its flagship product, SM03, in November last year and expects to commercialize SM03 soon after the clinical data readout this year. In addition, SN1011, a key product of the Company, completed its phase I last subject last visit in China in July last year. The Company is currently initiating a phase II clinical study in China for pemphigus vulgaris (PV), and also plans to initiate a phase II clinical study for systemic lupus erythematosus (SLE) in the near future. SM17, the Company’s another key product, is also expected to enter clinical stage this year.

For business development, in September last year, the Company entered into its first license agreement to grant rights for developing and commercializing the Company’s key product, SN1011, in the field of renal disease on a global basis. This license provided the Company with an initial upfront payment of US$12 million and the development and sales milestone payments of up to US$183 million. To enhance its R&D and product development capabilities, the Company is constructing a new plant with a capacity of more than 32,000 liters in the Suzhou Industrial Park, and has held a topping-out ceremony for the new base earlier.

Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: “The Company is honored to be awarded the “Best Small and Mid-Cap Company” and “Best CEO” in the selection of the “6th Hong Kong Golden Stocks Awards” and the “Listed Companies with the Most Growth Potential” in the selection of “2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies”, respectively. That reflects the capital market’s recognition of the value, management and growth potential of the Company and is a great encouragement to the Company. In the future, the Company will, in line with its original purposes, endeavor to discover and develop innovative drug targets, explore therapies for immune diseases, further expand its product pipeline and strive to bring benefits to patients; strengthen its position in the capital market, enhance its overall competitiveness and create returns for shareholders and investors. With the imminent completion of the phase III clinical trial of its flagship product SM03, the Company is poised for a new leap of increase in value.”

About the Selection of the “6th Hong Kong Golden Stocks Awards”
The selection of the “6th Hong Kong Golden Stocks Awards” was jointly organized by Zhitongcaijing.com, a leading Hong Kong and US stock information platform in China, with RoyalFlush Finance and China Galaxy Securities. This selection was rigorous and attracted over 1,000 entries from Hong Kong-listed companies, covering emerging industries such as telecommunications, chip manufacturing, Internet, medical and pharmaceuticals, which are leading the transformation of China’s economy.

About the Selection of “2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies”
Organised by Sina Finance and supported by Valuable Capital, the selection of “2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies” was based on a combination of financial and other quantitative indicators, expert evaluation and online voting.

About SinoMab BioScience Limited
SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin’s lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.






Topic: Press release summary

Selection Trial for Direct Enrolment of Meritorious Sportsmen in the Rank of Havildar in the Army into ASC Centre (South) – 2 ATC, Bangalore-07

Feb 19, 2021 | Business

Selection trials for Direct Enrolment of Meritorious sportsmen (Male) with age 171/2 to 22 years of age as on 31 Dec 2021 with education qualification matriculation or equivalent examination who have represented State/ Country in National/ International completions either at Senior or at Junior level University Sports Board or represented the State School teams in the National Sports or Games for School conducted by the All India School teams in the rank of Havildar in the Army into ASC Sports Teams of (Body Building, Volleyball, Swimming, Basketball, Cricket & Football) at ASC Centre (South) – 2 ATC, Bangalore wef04 Mar 2021.